Aligos Therapeutics' average one-year price target was raised to $67.12 per share from $39.27, a 70.91% increase. The revision is a positive analyst signal for the biotech name, though the article is limited to consensus target updates rather than operating or clinical fundamentals. Market impact should be modest, but the change may support sentiment in the stock.
Aligos Therapeutics' average one-year price target was raised to $67.12 per share from $39.27, a 70.91% increase. The revision is a positive analyst signal for the biotech name, though the article is limited to consensus target updates rather than operating or clinical fundamentals. Market impact should be modest, but the change may support sentiment in the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
